SYK interacts with FLT3 (173), and thus targeting SYK with entospletinib may be effective in FLT3-mutated AML and is currently under investigation (NCT02343939, NCT03135028, NCT03013998) (Table 2). Here, SYK is linked to acute myeloid leukemia.